Next Generation Sequencing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

The Global Next Generation Sequencing Services Market is anticipated to expand from USD 6.09 Billion in 2025 to USD 21.38 Billion by 2031, exhibiting a compound annual growth rate of 23.28%. These services involve applying advanced high-throughput technologies to identify the precise sequence of nucleotides in RNA or DNA molecules, covering everything from sample preparation and library building to the actual sequencing and bioinformatics assessment. This methodology delivers reliable and swift genetic insights for a variety of clinical and research applications. The growth of this market is primarily fueled by the steady decline in sequencing expenses, the growing incorporation of these services into companion diagnostics and personalized healthcare, and continuous improvements in platform technology that boost both precision and processing speed.

Extensive collaboration defines the worldwide genomics network backing these services, as demonstrated by the Global Alliance for Genomics and Health (GA4GH). In April 2026, this major industry group noted that over 500 premier organizations are actively involved in promoting the responsible utilization of genomic data. Nevertheless, even with this strong collaborative spirit and impressive market growth, major obstacles continue to hinder broader expansion. Chief among these are the intricate nature and substantial expenses tied to processing, analyzing, and interpreting the massive volumes of genomic information produced by these platforms, compounded by ongoing ethical and data privacy concerns.

Market Driver

A major force propelling the Global Next Generation Sequencing Services Market is the steady decline in the costs associated with sequencing. While historically posing a formidable hurdle, the lowering expense of sequencing a genome has broadened access to vital genetic data, facilitating expanded clinical and research uses. This shift is clearly reflected in technological upgrades that improve throughput and simplify sequencing processes. As an example, PacBio announced in October 2025 that its updated SPRQ-Nx sequencing chemistry aims to produce a HiFi genome at scale for under $300, marking a cost decrease of up to 40%. These financial efficiencies facilitate more extensive genomic research, quickening the incorporation of sequencing technologies into standard diagnostic practices.

Another vital element stimulating market growth is the rising implementation of companion diagnostics and precision medicine. With the medical field moving toward individualized care, these sequencing services play an essential role in pinpointing genetic mutations that guide targeted treatments and enhance patient results. This trend is especially noticeable in cancer care; a February 2026 Sermo poll revealed that 35% of doctors cited oncology as the primary clinical setting for considering such sequencing tests. The creation and regulatory clearance of sequencing-backed companion diagnostics enable accurate patient categorization, driving the need for thorough genomic assessments. Furthermore, government backing highlights the significance of this sector, as seen on the European Union's Funding & Tenders Portal, which notes the Genomic Data Infrastructure project is operating with a budget exceeding 40 million EUR through October 2026 to establish a federated, cross-border network of national genome repositories.

Market Challenge

A major barrier to the growth of the market is the intricate nature and steep expenses linked to the management, analysis, and interpretation of the immense volumes of genomic data produced by these sequencing platforms. Overcoming this hurdle requires significant investments in solid technological infrastructure, tailored software solutions, and a team of expertly trained bioinformatics specialists. The massive scale and complex detail of this genetic information necessitate powerful computing resources and professional evaluation, resulting in heavy operational costs for end-users as well as service providers.

The massive financial commitment needed to properly manage genomic data acts as a direct limitation on the broad implementation and scalability of these sequencing services. For example, the European Commission points out that the Genomic Data Infrastructure (GDI) initiative, created to provide secure access to clinical and genomic data throughout Europe, requires a €40 million co-funding investment from November 2022 to October 2026, underscoring the hefty costs of establishing essential data handling systems. These monetary obstacles, combined with the continuous requirement for sophisticated data evaluation, often discourage smaller clinical labs and research facilities from fully adopting these services, which ultimately hinders the market's overall expansion and restricts wider access to critical genomic discoveries.

Market Trends

The incorporation of sophisticated Artificial Intelligence and Machine Learning into data analysis is drastically improving the effectiveness and value of sequencing services by optimizing complicated bioinformatics processes. This development helps overcome the difficulties of deciphering massive datasets, quickly turning unprocessed genetic data into practical applications. Integrating these technologies enables superior variant calling and pattern identification, surpassing traditional manual computing techniques. In fact, a February 2026 NVIDIA survey on the State of AI in Healthcare and Life Sciences indicated that 70% of professionals in these fields are currently utilizing AI within their workflows. Such extensive implementation is essential for speeding up pharmaceutical research and customizing medical treatments through a more profound comprehension of disease pathways.

Another crucial trend is the growing use of multiomic and single-cell sequencing techniques, which afford a much more detailed view of biological mechanisms compared to standard bulk sequencing. Single-cell methods empower scientists to investigate the diversity among cell groups and identify uncommon cells with exceptional clarity. Meanwhile, multiomic strategies combine information across different biological layers, including proteomics and genomics, to deliver a comprehensive perspective on diseases and cellular activities. This synthesized approach is exceptionally beneficial in disciplines such as immunology and oncology for tracking how diseases advance and how they react to therapies. Reflecting this shift, 10x Genomics noted in January 2026 that sales of single-cell consumables had risen by over 20% from the previous year, demonstrating the rapid adoption of these sophisticated methods and emphasizing the escalating need for the precise biological data they provide.

Key Market Players

• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• BGI Genomics Co., Ltd.
• Eurofins Scientific SE
• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• PerkinElmer Inc.
• Macrogen, Inc.
• GENEWIZ, Inc.

Report Scope

In this report, the Global Next Generation Sequencing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Sequencing Services Market, By Service:

• Human Genome Sequencing Services
• Single Cell Sequencing Services
• Microbial Genome-based Sequencing Services
• Gene Regulation Services
• Others

Next Generation Sequencing Services Market, By Workflow:

• Pre-Sequencing
• Sequencing
• Data Analysis

Next Generation Sequencing Services Market, By End User:

• Hospitals & Clinics
• Academic & Research Institutions
• Pharmaceutical & Biotechnology Companies
• Others

Next Generation Sequencing Services Market, By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Sequencing Services Market.

Available Customizations

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.